Overview

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation study of ARQ 197 administered orally in combination with sorafenib.
Phase:
Phase 1
Details
Lead Sponsor:
ArQule
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
Treatments:
Niacinamide
Sorafenib